Please login to the form below

Not currently logged in
Email:
Password:

VX-135

This page shows the latest VX-135 news and features for those working in and with pharma, biotech and healthcare.

Gilead files oral hepatitis C drug sofosbuvir in US

Gilead files oral hepatitis C drug sofosbuvir in US

However, BMS has recently signed a deal with Vertex Pharmaceuticals to partner on a clinical investigating a combination of the BMS candidate daclatasvir and Vertex' uridine nucleotide analogue VX-135.

Latest news

  • BMS and Vertex partner on oral hepatitis treatment BMS and Vertex partner on oral hepatitis treatment

    VX-135 is a uridine nucleotide analogue that, like BMS-986094, is designed to affect the NS5B polymerase to inhibit the replication the hepatitis C virus. ... GSK2336805. In addition, Vertex is planning to test the use of VX-135 along with Incivek

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....